FR2920776B1 - Utilisation de derives de purine pour la fabrication d'un medicament - Google Patents

Utilisation de derives de purine pour la fabrication d'un medicament

Info

Publication number
FR2920776B1
FR2920776B1 FR0706390A FR0706390A FR2920776B1 FR 2920776 B1 FR2920776 B1 FR 2920776B1 FR 0706390 A FR0706390 A FR 0706390A FR 0706390 A FR0706390 A FR 0706390A FR 2920776 B1 FR2920776 B1 FR 2920776B1
Authority
FR
France
Prior art keywords
manufacture
medicinal product
purine derivatives
purine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0706390A
Other languages
English (en)
French (fr)
Other versions
FR2920776A1 (fr
Inventor
Laurent Meijer
Karima Bettayeb
Herve Galons
Nassima Oumata
Christian Berthou
Karine Lester
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Rennes 1
Universite Paris Descartes
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Rennes 1
Universite Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0706390A priority Critical patent/FR2920776B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Rennes 1, Universite Paris Descartes filed Critical Centre National de la Recherche Scientifique CNRS
Priority to JP2010524542A priority patent/JP5485893B2/ja
Priority to CA2699590A priority patent/CA2699590A1/fr
Priority to US12/675,945 priority patent/US8431583B2/en
Priority to PCT/FR2008/001278 priority patent/WO2009068761A2/fr
Priority to DK08855583.4T priority patent/DK2187889T3/da
Priority to KR1020107007886A priority patent/KR20100075908A/ko
Priority to EP08855583.4A priority patent/EP2187889B1/fr
Priority to MX2010002680A priority patent/MX2010002680A/es
Priority to CN2008801067270A priority patent/CN101918000B/zh
Priority to BRPI0816810A priority patent/BRPI0816810A2/pt
Priority to RU2010108505/15A priority patent/RU2500400C2/ru
Priority to ES08855583.4T priority patent/ES2444419T3/es
Publication of FR2920776A1 publication Critical patent/FR2920776A1/fr
Application granted granted Critical
Publication of FR2920776B1 publication Critical patent/FR2920776B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0706390A 2007-09-12 2007-09-12 Utilisation de derives de purine pour la fabrication d'un medicament Active FR2920776B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR0706390A FR2920776B1 (fr) 2007-09-12 2007-09-12 Utilisation de derives de purine pour la fabrication d'un medicament
BRPI0816810A BRPI0816810A2 (pt) 2007-09-12 2008-09-12 utilização de pelo menos um composto, e, composto.
US12/675,945 US8431583B2 (en) 2007-09-12 2008-09-12 Use of purine derivatives for the manufacture of a medicament
PCT/FR2008/001278 WO2009068761A2 (fr) 2007-09-12 2008-09-12 Utilisation de derives de purine pour la fabrication d'un medicament
DK08855583.4T DK2187889T3 (da) 2007-09-12 2008-09-12 Anvendelse af purinderivater til fremstilling af et lægemiddel
KR1020107007886A KR20100075908A (ko) 2007-09-12 2008-09-12 약제 제조용 퓨린 유도체의 용도
JP2010524542A JP5485893B2 (ja) 2007-09-12 2008-09-12 医薬品の製造のためにプリン誘導体を使用する方法
MX2010002680A MX2010002680A (es) 2007-09-12 2008-09-12 Uso de derivados de purina para la manufactura de un medicamento.
CN2008801067270A CN101918000B (zh) 2007-09-12 2008-09-12 嘌呤衍生物在制备药物中的用途
CA2699590A CA2699590A1 (fr) 2007-09-12 2008-09-12 Utilisation de derives de purine pour la fabrication d'un medicament
RU2010108505/15A RU2500400C2 (ru) 2007-09-12 2008-09-12 Применение производных пурина для изготовления лекарственного препарата
ES08855583.4T ES2444419T3 (es) 2007-09-12 2008-09-12 Utilización de derivados de purina para la preparación de un medicamento
EP08855583.4A EP2187889B1 (fr) 2007-09-12 2008-09-12 Utilisation de derives de purine pour la fabrication d'un medicament

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0706390A FR2920776B1 (fr) 2007-09-12 2007-09-12 Utilisation de derives de purine pour la fabrication d'un medicament

Publications (2)

Publication Number Publication Date
FR2920776A1 FR2920776A1 (fr) 2009-03-13
FR2920776B1 true FR2920776B1 (fr) 2012-09-28

Family

ID=39382006

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0706390A Active FR2920776B1 (fr) 2007-09-12 2007-09-12 Utilisation de derives de purine pour la fabrication d'un medicament

Country Status (13)

Country Link
US (1) US8431583B2 (enExample)
EP (1) EP2187889B1 (enExample)
JP (1) JP5485893B2 (enExample)
KR (1) KR20100075908A (enExample)
CN (1) CN101918000B (enExample)
BR (1) BRPI0816810A2 (enExample)
CA (1) CA2699590A1 (enExample)
DK (1) DK2187889T3 (enExample)
ES (1) ES2444419T3 (enExample)
FR (1) FR2920776B1 (enExample)
MX (1) MX2010002680A (enExample)
RU (1) RU2500400C2 (enExample)
WO (1) WO2009068761A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2920776B1 (fr) 2007-09-12 2012-09-28 Centre Nat Rech Scient Utilisation de derives de purine pour la fabrication d'un medicament
WO2010103473A1 (en) * 2009-03-10 2010-09-16 Chu De Brest Method of treatment of polycystic diseases and chronic lymphocytic leukemia
WO2013130461A1 (en) * 2012-02-29 2013-09-06 The Scripps Research Institute Wee1 degradation inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6969720B2 (en) * 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
DE60205376T2 (de) * 2001-06-27 2006-04-06 Cyclacel Ltd. 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
US6812232B2 (en) * 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
GB0315259D0 (en) 2003-06-30 2003-08-06 Cyclacel Ltd Use
AU2004264419B2 (en) * 2003-08-15 2009-01-15 Irm Llc 6-substituted anilino purines as RTK inhibitors
FR2920776B1 (fr) 2007-09-12 2012-09-28 Centre Nat Rech Scient Utilisation de derives de purine pour la fabrication d'un medicament

Also Published As

Publication number Publication date
ES2444419T3 (es) 2014-02-25
KR20100075908A (ko) 2010-07-05
DK2187889T3 (da) 2014-02-03
BRPI0816810A2 (pt) 2017-05-16
RU2500400C2 (ru) 2013-12-10
CA2699590A1 (fr) 2009-06-04
WO2009068761A3 (fr) 2010-01-07
RU2010108505A (ru) 2011-10-20
FR2920776A1 (fr) 2009-03-13
CN101918000B (zh) 2012-11-21
EP2187889A2 (fr) 2010-05-26
CN101918000A (zh) 2010-12-15
US20100311768A1 (en) 2010-12-09
EP2187889B1 (fr) 2013-11-06
JP2010539146A (ja) 2010-12-16
JP5485893B2 (ja) 2014-05-07
MX2010002680A (es) 2010-08-26
WO2009068761A2 (fr) 2009-06-04
US8431583B2 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
FR2959416B1 (fr) Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
FR2894145B1 (fr) Utilisation de facteur h du complement a titre de medicament
EP2702976A4 (en) Container for administering medication
FR2920776B1 (fr) Utilisation de derives de purine pour la fabrication d'un medicament
PL2121277T3 (pl) Sposób wytwarzania opakowań dla produktów kosmetycznych, leczniczych, farmaceutycznych i tym podobnych
FR2898272B1 (fr) Utilisation de derives du 3,5-seco-4-nor-cholestrane pour l'obtention d'un medicament cytoprotecteur
FR2930434B1 (fr) Utilisation d'une argile organophile pour la realisation de masques auto-gelifiants a usage cosmetique
EP2452949A4 (en) USE OF CARBOHYANANEASE II FOR THE PREPARATION OF A MEDICAMENT
FR2904318B1 (fr) Derives de pyrimidinone et leur utilisation comme medicament
FR2945951B1 (fr) Composition d'akg et son utilisation pour la fabrication d'un medicament.
FR2896690B1 (fr) Utilisation de l'enantiomere(s) de la mequitazine pour la preparation d'un medicament, tout en limitant la toxicite genomique
FR2917623B1 (fr) Utilisation d'un probiotique pour la prevention des infections des voies respiratoires
UA10680S (uk) Упаковка фармацевтичного засобу «корвалол-новий-дарниця»
UA41765S (uk) Упаковка для лікарського засобу «пен-герпевір»
UA17193S (uk) Упаковка для лікарського засобу «лоризан»
UA17318S (uk) Упаковка для лікарського засобу «гліцисед»
UA18038S (uk) Упаковка для лікарського засобу «нуклеїнат»
UA18843S (uk) Упаковка для лікарського засобу «тіотриазолін»
UA41497S (uk) Етикетка для лікарського засобу «ергоцетал»
UA41496S (uk) Етикетка для лікарського засобу «церегліа»
UA41832S (uk) Етикетка для лікарського засобу «гіацинтія»
UA41500S (uk) Етикетка для лікарського засобу «аскорбінка-кв»
UA41834S (uk) Етикетка для лікарського засобу «феміклін»
UA41499S (uk) Етикетка для лікарського засобу «афлетин»
UA18096S (uk) Упаковка для фармацевтичного виробу «генферон»

Legal Events

Date Code Title Description
CD Change of name or company name
TQ Partial transmission of property
PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11